The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study
John F. Seymour(The Royal Melbourne Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Lori A. Gressick(AbbVie (United States)), Cathy E. Nolan(Abbott Fund), Sari H. Enschede(AbbVie (United States)), Thomas J. Kipps(University of California San Diego), David C.S. Huang(Indonesia International Institute for Life Sciences), John M. Pagel(University of Washington), David E. Darden(Abbott Fund), Alison M. Graham(Abbott Fund), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Dana-Farber Cancer Institute), Brenda Chyla(AbbVie (United States)), Brad S. Kahl(UW Health University Hospital), William G. Wierda(University of Maryland, Baltimore), Mary Ann Anderson(The Royal Melbourne Hospital), Thomas P. Miller(Queen Elizabeth University Hospital), Elisa Cerri(AbbVie (United States)), Todd Busman(Abbott Fund), Hao Xiong(Shanghai Jiao Tong University)
Cited by 10
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k